Rosetta Genomics Reports Second Quarter 2008 Financi...(al to form the basisfor a new class of d...)

Date:8/19/2008

al to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNAs. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The first microRNA diagnostic test applying Rosetta Genomics' technology has been approved for clinical use by the State of New York, and the company expects it will be launched by licensed clinical laboratories in the United States in 2008.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the development of therapeutics and diagnostic products, the progress and timing of our diagnostic and therapeutic programs, including the expected laun
'/>"/>

SOURCE Rosetta Genomics Ltd Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
2. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
3. Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference
4. Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
5. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
6. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
7. /C O R R E C T I O N -- Rosetta Genomics Ltd/
8. Rosetta Genomics Reports First Quarter 2008 Financial Results
9. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
10. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
11. Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference